ZUG, Switzerland, January 6, 2025 – Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced ...

Sungkyunkwan University researchers in Korea ran a nationwide cohort analysis linking allergic diseases to increased optic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 2 ACUITY trial met its primary safety endpoint ...

Optic neuropathies including glaucoma, traumatic injury, ischemic damage, and optic neuritis, are the leading causes of irreversible blindness ...

Optic neuritis is a rare autoimmune disease characterized by the inflammation of the optic nerve. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TRE-515 for the ...

A nationwide cohort study of more than 4 million adults showed that people with allergic diseases were nearly one third more likely to develop optic neuritis than those without such conditions, with ...

Erythropoietin (EPO), shown in early studies to potentially provide neuroprotection for patients with optic neuritis, failed to provide any significant neuroprotection in comparison with placebo in a ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...

OCS-05 showed a favorable safety and tolerability profile compared to placebo Achieved statistically significant results on key secondary efficacy endpoints compared to placebo, including objective ...